Solanezumab for Preclinical Alzheimer ' s: Phase 3 Data Solanezumab for Preclinical Alzheimer ' s: Phase 3 Data

Solanezumab, a monoclonal antibody that binds to the monomeric or soluble form of amyloid-beta, is no better than placebo in slowing the progression of preclinical Alzheimer ' s, results of a phase 3 trial show.Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Psychiatry News Source Type: news